Stifel Maintains Buy Rating for Revolution Medicines: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Stifel has maintained its Buy rating for Revolution Medicines (NASDAQ:RVMD) and increased its price target from $37.00 to $47.00. The shares of Revolution Medicines are currently trading at $29.79, up 0.2% over the last 24 hours. A move to $47.00 would represent a 57.77% increase from the current share price.
September 21, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel's maintained Buy rating and increased price target for Revolution Medicines could potentially drive the stock price up in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and trading behavior. In this case, Stifel's maintained Buy rating and increased price target for Revolution Medicines could potentially attract more investors to the stock, driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100